Awaiting development: Guidance and quality standards

Showing 1 to 10 of 15

Guidance and quality standards awaiting development
Title	Type
Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]	Technology appraisal guidance
Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [GID-TA12003]	Technology appraisal guidance
Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]	Technology appraisal guidance
Pembrolizumab for treating advanced or recurrent endometrial cancer with mismatch repair deficiency [ID6710]	Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]	Technology appraisal guidance
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]	Technology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808]	Technology appraisal guidance